Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria

Diabetes Care. 2007 Dec;30(12):3122-4. doi: 10.2337/dc07-0919. Epub 2007 Sep 5.

Authors

Birgitte Nellemann¹, Lars C Gormsen, Jens Dollerup, Ole Schmitz, Carl E Mogensen, Lars M Rasmussen, Søren Nielsen

Affiliation

¹ Medical Department M, Aarhus University Hospital, Aarhus, Denmark.

PMID: 17804683
DOI: 10.2337/dc07-0919

No abstract available

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Albuminuria / blood
Atherosclerosis / prevention & control
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / urine
Diabetic Angiopathies / prevention & control
Diabetic Nephropathies / blood
Diabetic Nephropathies / drug therapy
Double-Blind Method
Enzyme-Linked Immunosorbent Assay
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Male
Osteoprotegerin / blood*
Simvastatin / therapeutic use*

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Osteoprotegerin
Simvastatin

Associated data

ClinicalTrials.gov/NCT00471549